Company profile: Haselmeier
1.1 - Company Overview
Company description
- Provider of innovative self-injection devices, including pen injectors and other systems for self injection, featuring proprietary designs, technology and intellectual property. With over four decades of medical device experience, the company offers a world-class design and development team working in compliance with regulatory requirements.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Haselmeier
Leon Nanodrugs
HQ: Germany
Website
- Description: Provider of nanotechnology-based drug development, offering access to next-generation nano-formulated drugs, specialized product development of enhanced versions of existing products, and services enabling pre-clinical and clinical formulations for clients’ NCEs or branded drugs. Products include FR-JET System, NANOlab, NANOme, and NANOus for scalable, GMP-compliant nanocarrier manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leon Nanodrugs company profile →
EryDel
HQ: Italy
Website
- Description: Provider of red blood cell-based drug delivery technologies and therapies. Offers the AIDE platform for autologous intracellular drug encapsulation, the CE marked Red Cell Loader device and EryKit for point-of-care loading, and EryDex, a patient-specific dexamethasone sodium phosphate treatment for Ataxia-Telangiectasia; conducting the NEAT Phase 3 trial evaluating EryDex's neurological effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EryDel company profile →
Xeris Biopharma
HQ: United States
Website
- Description: Provider of pharmaceutical therapies in endocrinology, neurology, and gastroenterology, including Gvoke and Ogluo ready-to-use glucagon injections for severe hypoglycemia; Keveyis, the first FDA-approved treatment for Primary Periodic Paralysis; Recorlev for endogenous Cushing's syndrome; and levothyroxine for hypothyroidism. Ogluo is marketed in the UK/EU under an exclusive agreement with Tetris Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xeris Biopharma company profile →
Vivani Medical
HQ: United States
Website
- Description: Provider of implantable visual prosthetics for blind individuals and developer of NanoPortal technology for miniature, subdermal drug implants delivering steady medication, including NPM-115 for chronic weight management and NPM-119 (under development) for type 2 diabetes; via subsidiary Cortigent, develops targeted neurostimulation for artificial vision and muscle movement restoration in stroke rehabilitation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivani Medical company profile →
IntelGenx
HQ: Canada
Website
- Description: Provider of oral drug delivery technologies focused on developing and manufacturing pharmaceutical oral films, transmucosal films, and transdermal patches. Solutions include VersaFilm and DisinteQ for rapidly dissolving oral films, VetaFilm for veterinary films for pets, Transmucosal Films for buccal/sublingual absorption, and VevaDerm for extended-release patches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IntelGenx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Haselmeier
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Haselmeier
2.2 - Growth funds investing in similar companies to Haselmeier
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Haselmeier
4.2 - Public trading comparable groups for Haselmeier
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →